Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Deborah Donnell et al.|The Lancet HIV|2023Cited by 14
HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP studyChristina Psaros, Georgia R. Goodman, Jasper S. Lee et al.|Journal of the International AIDS Society|2024Cited by 9
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialAdeola Adeyeye, Zhe Wang, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 0